• Solid execution, improving earnings visibility – Q1-2 FY9/26 results were ahead of expectations, driven by a combination of firm domestic demand in Fine Chemicals involving favorable price revisions, and a return to a robust growth profile YoY in Life Sciences. Management is executing well under challenging macro conditions, and also provided further insight into upcoming projects in Sustainability (deep ocean mineral resources and offshore wind power), which highlights 1) the company’s strong positioning for future growth, and 2) improving longer-term earnings visibility. The company has raised its FY9/26 guidance and DPS (from ¥58 to ¥60) and announced a 2-for-1 share split, signaling a prioritization of shareholder returns.
21 May 2026
Sanyo Trading (3176) Q2 FY9/26 results update: Gearing up for improving returns
Sanyo Trading Co., Ltd. (3176:TKS), 0 | Itochu Corporation (8001:TKS), 0 | Mitsubishi Corporation (8058:TKS), 0 | Mitsui & Co.,Ltd (8031:TKS), 0 | Sumitomo Corporation (8053:TKS), 0 | Marubeni Corporation (8002:TKS), 0 | Kanematsu Corporation (8020:TKS), 0 | Nagase & Co., Ltd. (8012:TKS), 0 | Inabata & Co., Ltd. (8098:TKS), 0 | Okaya & Co., Ltd. (7485:NGO), 0 | Kanaden Corporation (8081:TKS), 0 | Meiwa Corporation (8103:TKS), 0 | Seika Corporation (8061:TKS), 0 | ReproCELL Inc. (4978:TKS), 0 | Cosmo Bio Co., Ltd. (3386:TKS), 0 | Brenntag SE (BNR:ETR), 0 | Rexel SA (RXL:PAR), 0 | Azelis Group N.V. (AZE:BRU), 0 | IMCD N.V. (IMCD:AMS), 0 | Advanced Information Technology Public Co., Ltd. (AIT:BKK), 0 | Babcock & Wilcox Enterprises Inc (BW:NYS), 0 | Avantor, Inc. (AVTR:NYS), 0
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Sanyo Trading (3176) Q2 FY9/26 results update: Gearing up for improving returns
Sanyo Trading Co., Ltd. (3176:TKS), 0 | Itochu Corporation (8001:TKS), 0 | Mitsubishi Corporation (8058:TKS), 0 | Mitsui & Co.,Ltd (8031:TKS), 0 | Sumitomo Corporation (8053:TKS), 0 | Marubeni Corporation (8002:TKS), 0 | Kanematsu Corporation (8020:TKS), 0 | Nagase & Co., Ltd. (8012:TKS), 0 | Inabata & Co., Ltd. (8098:TKS), 0 | Okaya & Co., Ltd. (7485:NGO), 0 | Kanaden Corporation (8081:TKS), 0 | Meiwa Corporation (8103:TKS), 0 | Seika Corporation (8061:TKS), 0 | ReproCELL Inc. (4978:TKS), 0 | Cosmo Bio Co., Ltd. (3386:TKS), 0 | Brenntag SE (BNR:ETR), 0 | Rexel SA (RXL:PAR), 0 | Azelis Group N.V. (AZE:BRU), 0 | IMCD N.V. (IMCD:AMS), 0 | Advanced Information Technology Public Co., Ltd. (AIT:BKK), 0 | Babcock & Wilcox Enterprises Inc (BW:NYS), 0 | Avantor, Inc. (AVTR:NYS), 0
- Published:
21 May 2026 - Author:
-
Pages:
12 -
• Solid execution, improving earnings visibility – Q1-2 FY9/26 results were ahead of expectations, driven by a combination of firm domestic demand in Fine Chemicals involving favorable price revisions, and a return to a robust growth profile YoY in Life Sciences. Management is executing well under challenging macro conditions, and also provided further insight into upcoming projects in Sustainability (deep ocean mineral resources and offshore wind power), which highlights 1) the company’s strong positioning for future growth, and 2) improving longer-term earnings visibility. The company has raised its FY9/26 guidance and DPS (from ¥58 to ¥60) and announced a 2-for-1 share split, signaling a prioritization of shareholder returns.